-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Genmab, Lowers Price Target to $37

Benzinga·04/09/2025 11:45:43
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $50 to $37.